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Plasma FK506 was studied in 49 liver, 13 heart, 3 
double-lung or heart-lung, and 21 kidney recipients. 
The levels were correlated with the drug doses used, 
kidney function, and liver function. In all varieties of 
recipients, there was an early rise in the FK506 plasma 
levels that occurred at the time of intravenous admin-
istration of the drug. At the same time or shortly after, 
there were increases in serum creatinine that were tran-
sitory except in liver recipients with continuing subop-
timal graft function. The quality of hepatic function 
dominated all aspects of FK506 management in the liver 
recipients. Those who received well-functioning grafts 
could be given about the same drug doses as recipients 
of kidneys and the thoracic organs. Liver recipients with 
defective grafts had astronomical rises in plasma 
FK506, a high incidence of renal failure, and probably 
increased neurotoxicity. In kidney transplant recipi-
ents, the FK506 plasma levels and doses were essentially 
the same in patients with prompt versus delayed renal 
function. These studies have highlighted the necessity, 
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first, of close pharmacologic monitoring of patients who 
are given FK506 in the presence of abnormal liver 
function, and second, of using smaller intravenous in-
duction doses than in past practice. 
FK506 has been in use clinically for almost 18 months (I-
5). After liver transplantation, we have noticed that the quality 
of liver graft function dramatically influences the doses and 
trough levels of FK506, as well as the quality of renal function. 
We describe here the interrelation of these parameters after 
liver transplantation; transplantation of hearts, lungs, and 
heart-lungs; and after the transplantation of cadaver kidneys 
with either prompt or delayed function. From this study has 
come a better understanding of how management policies in-
terrelate with the different kinds of transplantation. 
MATERIALS AND METHODS 
Case material. Eighty-seven adults who were 17-69 years old (45.4± 
13.6 SO) underwent transplantation between October 13, 1989 and 
May 17, 1990. Follow-ups were to August 1, 1990. The male/female 
ratio was 47/40. Patients were included only if there were frequent 
FK506 plasma trough determinations within the 60-day study period. 
Samples were drawn on Mondays and Thursdays in most patients, or 
at the time of outpatient visits after discharge. Liver recipients were 
not included for analysis if a postoperative diagnosis was made of 
hepatic artery thrombosis or stenosis, biliary leak, and biliary stricture. 
Heart transplantation (n = 13). Because one objective was to deter-
mine the effect of kidney and liver function on FK506 doses and plasma 
72 TRANSPLANTATION Vol. 52, No.1 
levels, the thoracic organ recipients provided the most complete infor-
mation. None of them had known intrinsic renal or hepatic disease 
preoperatively. Four of the 13 adult recipients were from a series 
recently reported by Armitage et a!. (5). Pretransplant mechanical 
circulatory support had been required in 6 (46%) of the 13 patients; 5 
had the Novacor left ventricular assist device (LVAD)* and the other 
was maintained with an intraaortic balloon pump (IABP). 
One other patient not included in the study group had been main-
tained for several weeks on a left ventricular assist device preopera-
tively. He had a cardiac arrest during preparation for transplantation 
and was administered cardiac massage until cardiopulmonary bypass 
could be instituted. His heart transplant functioned well, but the results 
from his FK506 studies as well as his postoperative clinical course were 
so different from the others that his case will be documented separately. 
Double-lung (n = 2) and heart-lung (n = 1) transplantation. These 
patients were 26, 33, and 27 years old. Both double-lung recipients had 
cystic fibrosis, and the heart-lung recipient had Eisenmenger's complex. 
These patients have been mentioned in other reports (3, 5). 
Kidney transplantation (n = 21). Fifteen patients underwent primary 
cadaveric transplantation and 6 were undergoing cadaveric retrans-
plantation. None was known to have liver disease. They were stratified 
into those (n = 14) who had prompt graft function with sustained 
freedom from dialysis throughout the 2-month period of study, and 
those (n = 7) who had acute tubular necrosis requiring dialysis for 3-
20 days during graft recovery. 
Liver transplantation (n = 49). The 49 liver recipients were free of 
intrinsic chronic kidney disease, although 7 (14.3%) had hepatorenal 
syndrome not requiring dialysis and 4 more (8.2%) were on dialysis at 
the time of their liver replacement. Although 47 (95%) of the 49 patients 
survived, they could be stratified into 4 postoperative subgroups defined 
mainly by the quality of liver graft function and, to a lesser degree, by 
the rapidity of recovery from intensive care needs. Class I patients (n 
= 14) did not have evidence of major graft ischemia (SGPT <500 IU/ 
L in the first 5 days) and became jaundice-free with a serum bilirubin 
<2 mg% by 10 days. They were removed from ventilator assistance and 
extubated within 3 days. Class II patients (n = 17) had early rises in 
SGPT of >2000 IU/L with delayed resolution of jaundice until 10-20 
days. Ventilator dependence was for 3 to 9 days. Class III (n = 10) 
patients had highly variable evidence of acute ischemic injury, and slow 
resolution of jaundice in that the serum bilirubin did not fall to <2 
mg% until 20 to 45 days. Assisted ventilation was required for up to 30 
days. The Class IV patients (n = 8) had abnormally high serum 
bilirubins throughout the 60-day period of study and remained venti-
lator-dependent throughout this time. All patients in Class III and IV 
required parenteral hyperalimentation. The 2 deaths were of group IV 
patients who died of multiple organ failure and sepsis after 40 and 47 
days. 
Immunosuppression. The beginning therapeutic regimen was rela-
tively fixed for all of the organ recipients. Intravenous FK506 doses of 
0.075 mg/kg infused over 4 hr were started in the operating or recovery 
rooms and repeated every 12 hr until oral intake was started. When 
the conversion was made from intravenous to oral dosing at 0.15 mg/ 
kg every 12 hr, administration by both routes frequently was overlapped 
for one or 2 doses. Doses were reduced if there were suspected adverse 
drug reactions, or which nephrotoxicity and neurotoxicity were the 
most common. The warning parameters were an increase in serum 
creatinine above 2 mg%, BUN above 100 mg% and/or changes in the 
mental status concomitant with significant tremors. These were con-
sidered particularly ominous in the patients with evident hepatic graft 
dysfunction or in those with clinical and/or bacteriological evidence of 
sepsis. Most upward dose adjustments were prompted by a clinical 
suspicion of rejection, the histopathologic diagnosis of rejection, or the 
demonstration of plasma FK506 levels <0.5 ng/m!. For most of the 
study period, the plasma levels were not available until 4 or 5 days 
after the samples were taken. 
* Abbreviations: IABP, intraaortic balloon pump; LV AD, left ven-
tricular assist device. 
Prednisone usually was started at a daily dose of 20 mg, but in a 
number of the early patients a five-day steroid cycle was used, beginning 
at 200 mg perioperatively and finishing at 20 mg/day by the sixth 
postoperative day. By the end of two postoperative months, 13 (62%) 
and 27 (55%) of the kidney and liver recipients, respectively, were 
completely weaned from steroids as has been reported elsewhere in 
detail (6, 7). In contrast, only 2 (15%) of the cardiac recipients had 
steroids stopped in this period. The recipients of double lungs or a 
heart lung were not given steroids during the first 60 days. In these 3 
patients, FK506 oral doses were increased until rises in creatinine were 
seen. 
In addition to clinical criteria for guidance of therapy, protocol graft 
biopsies were obtained in the liver recipients after 10-14 days and 
again after 2 months. Biopsies in the heart recipients were obtained 
once a week throughout most of the first 2 months. Additional biopsies 
were obtained if there was evidence of rejection or graft dysfunction 
for unclear reasons. After kidney transplantation, the policy was to 
biopsy only for specific indications. 
Persistent rejection was treated with an increase in FK506. When 
there was not a satisfactory response or when there was renal dysfunc-
tion (creatinine 2:2 mg%), which precluded augmented FK506 therapy, 
daily steroid doses were increased or steroid boluses were given as 
described elsewhere (2, 3, 5). In 12 (13.8%) of the 87 patients, a 3-5 
day course of OKT3 was given (9 liver, 3 kidney, no hearts, lungs, or 
heart-lungs). 
FK506 monitoring. Trough plasma FK506 levels were determined 
with the enzyme immunoassay technique of Tamura et al. (8) twice 
per week or more often in complicated cases. This technique in our 
laboratory has a coefficient of variation of 22% at 0.5 ng/ml and 10% 
at 2.1 ng/m!. Most of the studies were performed during our learning 
curve with FK506, when optimal 12-hr trough levels were thought to 
be in the 0.5 to 1.5 ng/ml range. We now believe that the desirable 
range may be somewhat higher than this. However, results from the 
plasma determinations did not influence management because they 
were not available until days or even weeks later, especially in the first 
cases of the series. In most of the patients, the trough values were at 
12 hr since dosing was twice a day. However, in a few class III or IV 
patients whose FK506 was given once per day or every other day, the 
troughs were at 24 or 48 hr. 
Statistical analyses. The 60 days of the study were divided into 5-
day intervals. For each case, the mean was calculated for results of the 
biochemical tests and other parameters during the 5-day period. These 
mean values were pooled for all cases in the various groups and the 
means (±SE) were calculated. Single variable comparison between two 
or more different groups (classes) at each point was done with the 
unpaired t test and Bonferroni (Dunn) test, respectively. Signed rank 
comparisons with Bonferroni adjustment were used for serial analysis 
of changes in each parameter at different times and Kendall Tau test 
for the correlation between two variables with and without a lag time. 
The correlation between the individual mean values of simultaneously 
obtained serum bilirubin, FK506 plasma level, and drug dose in liver 
recipients was calculated over all time points of the study period using 
Spearman rank correlations. These were computed using SAS/PC 
version 6.03 (SAS Inst. Inc., Cary, NC). 
RESULTS 
Heart transplantation. During the first 5 postoperative days, 
all 13 patients were converted from intravenous to oral FK506. 
During these 5 days, the average plasma trough levels of FK506 
were higher (P>O.05) than at any subsequent time (Fig. 1). 
Oliguria or other evidence of renal dysfunction was common 
perioperatively, but maximal rises in the mean BUN or creat-
inine were delayed until the following 5-day period (Fig. 1). 
These improved subsequently, usually with minor adjustment 
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FIGURE 1. Renal function (mean ± SE), FK506 doses, and plasma 
FK506 levels in 13 adult heart recipients. 
of FK506 oral doses. None of the patients required dialysis. By 
the end of 60 days, the mean (±SD) of daily oral FK506 dose 
for all patients was 0.28±0.08 mg/kg, which was not signifi-
cantly less than the planned dose of 0.3 mg/kg. However, in 4 
of these patients who had elevated serum creatinine (;:::2 mg%) 
the daily doses had been significantly (P<0.05) reduced, with 
a mean of 0.19 ± 0.06 mg/kg. In the meanwhile, the mainte-
nance prednisone doses of 20 mg/day were slowly reduced for 
most patients throughout the entire 60-day period starting after 
the first 5 postoperative days (Fig. 1). 
An extraordinary increase in perioperative plasma FK506 
levels was seen in a 47-year-old patient (not included in the 
data of Fig. 1) who had been maintained on an LV AD for 
several weeks preoperatively and who had an irreversible car-
diac arrest just before his heart transplantation. He was treated 
with cardiac massage and emergency placement of an IABP 
until the institution of cardiopulmonary bypass. Administra-
tion of the usual induction dose of i.v. FK506 (0.15 mg/kg/day) 
caused an astronomical increase in the trough levels to a peak 
of 33 ng/ml, with a mean in the first 5 days of 23.3 ng/ml (Fig. 
2). Renal failure developed in the first postoperative day, ne-
cessitating 3 hemodialyses. He developed a paranoid psychosis 
at this time. With the reduced intravenous and oral FK506 
doses (about half of those usually given) shown in Figure 2, 
renal function returned to normal and the psychosis resolved. 
Prednisone was tapered rapidly (Fig. 2). Liver function tests 
were normal in this and all other heart recipients. 
Lung and heart-lung recipients. These 3 patients, who were 
on monotherapy with FK506, were able to take the drug orally 
within a few days (Fig. 3). Because steroids were avoided, the 
oral FK506 doses were increased to a limit imposed by renal 
dysfunction and presumed neurotoxicity. The creatinines and 
BUNs for the 3 patients are shown in Figure 3, as well as the 
FK506 doses. The principal acute rises in BUN and creatinine 
followed the intravenous treatment perioperatively (Fig. 3), but 
were later than in the heart recipients (Fig. 1). In 2 of the 3 
patients, eventual maintenance doses (0.45-0.5 mg/kg) were 
considerably higher than those normally given and were well 
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FIGURE 2. FK506 doses, high plasma FK506 levels, and renal dys· 
function requiring 3 dialyses in a heart recipient who had a cardiac 
arrest and prolonged massage just before transplantation. The evolu-
tion was atypical for a heart recipient and probably was due to multiple-
organ damage including the liver perioperatively. However, liver func-
tion tests were normal. Recovery was prompt and complete after a dose 
adjustment of FK506. 
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FIGURE 3. FK506 doses and plasma levels in 2 double· lung recipi-
ents and a heart-lung recipient who did not receive steroids. Rises in 
creatinine were used to determine the maximum FK506 doses. 
tolerated. Serious neurotoxicity and other adverse reactions 
were not seen. 
Kidney transplantation. The postoperative evolution of 
plasma FK506 levels in kidney recipients was similar to that of 
the heart, lung, and heart-lung recipients. The plasma FK506 
levels were highest during the perioperative intravenous induc-
tion and subsequently fell when the oral route was instituted 
(Fig. 4). These changes of plasma FK506 were not significantly 
different in 14 patients who had prompt renal graft function 
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FIGURE 4. Renal function (mean ± SE) plus dose and plasma levels 
in cadaver kidney recipients. Note that the presence or absence of ATN 
did not influence the FK506 kinetics insofar as this could be judged by 
trough levels. 
versus those (n = 7) who had ATN, with the exception of the 
5-10 and 50-55 day values (Fig. 4). All of the patients eventually 
had satisfactory results, with almost identical final renal func-
tion tests. Prednisone was weaned at a more rapid rate in 
patients whose new kidneys functioned at once (Fig. 4), al-
though the differences were not significant. By the end of 60 
days, the mean (±SE) daily prednisone dose was 2.5±1.6 mg 
for non-ATN (n = 14) and 6.31±1.8 mg for ATN (n = 7) 
patients. 
Liver transplantation. The number of patients, pre- and 
postoperative liver functions, and steroid use for each of classes 
I-IV are shown in Fig. 5. 
Classes I and II: Patients who had excellent or good liver 
graft function, short-term need for i.v. medication, and short 
stays in the intensive care units (class I and II) had an evolution 
of FK506 doses and trough levels similar to heart, lung, and 
renal recipients (Fig. 6). As with the other kinds of organ 
transplantation, the plasma levels were highest during i.v. 
administration. However, the eventual oral doses for these class 
I and II liver recipients were significantly less (P<0.05) than 
after renal and cardiac transplantation, which was reflected in 
lower plasma FK506 levels after day 10 (Fig. 6). The mean 
BUN and creatinine levels in the class I and II liver patients 
also were significantly lower (P<0.05) than in the cardiac 
recipients, especially in the early and late postoperative study 
period (Fig. 7). There was no new peri operative dialysis require-
ment in the class I and II liver recipients and in fact, a 
previously dialysis-bound patient in class II had restoration of 
renal function 21 days after transplant (Fig. 5). 
Classes III and IV: The therapeutic and plasma patterns in 
class I and II liver patients are shown separately in Figure 8 
and compared with the less-favored class III liver recipients 
and the severely ill class IV members who had protracted 
recovery of the graft and concurrent multiple organ dysfunc-
tion. FK506 was given intravenously for much longer times in 
class III and IV patients. Their plasma trough levels remained 
high even when downward dose adjustments were made. In 
class IV patients who all remained jaundiced for protracted 
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FIGURE 5. Stratification of liver recipients according to the graft 
function postoperatively. Categories were from the optimally function-
ing (class I) to the most seriously dysfunctional grafts (class IV). Note 
the shifting numbers (beginning with 4 before transplantation) of 
patients on dialysis. 
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FIGURE 6. FK506 doses and FK506 plasma levels in heart, kidney, 
and class I and II liver recipients. (OLTX) liver; (RTX) kidney; (HTX) 
heart. 
periods, plasma FK506 levels were astonishingly high for most 
of the first month, and up to 60 days they remained significantly 
elevated (P<O.05) compared with class I, II, and III patients 
(Fig. 8). Renal failure severe enough to require dialysis for the 
first time developed in 4 of the class III and 5 of the class IV 
patients, although this usually was reversible (Fig. 5). At the 
end of 60 days, 5 of the 13 patients who required early dialysis 
(including 4 on dialysis preoperatively) still needed this treat-
ment (Fig. 5). Four of the 5 have subsequently recovered from 
renal failure, leaving only one who currently is being weaned 
from dialysis. 
How ill class III and IV patients were in other ways was 
shown by the need for tracheostomy and ventilator dependence 
for many weeks or months in 12 of the 18 patients. However, 
16 of them survived, the only deaths being from multiple organ 
failure at 40 and 47 days in 2 class IV cases. Both were in a 
coma throughout most of their course. There were no deaths in 
the class I, II, or III patients. 
July 1991 ABU-ELMAGD ET AL. 75 
BUN 
(mg"" 
Creatinine 
(mg"" 
FK 506 
Plasma Level 
(ng/mll 
DAY 
FIGURE 7. FK506 doses, plasma level, and kidney function in liver 
(class I and II) and heart transplant patients. 
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FIGURE 8. The effect of postoperative liver function on FK506 doses 
and plasma levels. Note that the lowest doses and highest plasma levels 
were in the patients with unsatisfactory early hepatic function. 
Correlations of bilirubin, FK506 plasma levels, and drug dose: 
The correlation of bilirubin with plasma FK506 levels drawn 
on the same day is shown in Fig. 9A for patients ofthe combined 
classes I-IV. Although there was considerable scatter, the cor-
relation (r = 0.463) of these 2 parameters was significant (P = 
0.0001). 
The foregoing association between high serum bilirubin and 
high plasma FK506 levels could not be explained by increased 
FK506 doses, as might have been the case if the elevated serum 
bilirubins were ascribed to rejection. On the contrary, there 
was a significant (P = 0.0001) inverse correlation (r = -0.216) 
between the serum bilirubins and the FK506 doses (Fig. 9B), 
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FIGURE 9. Scatter plots for simultaneously determined serum bili-
rubin, FK506 plasma level, and drug dose on loglu scale in all liver 
recipients. Serum bilirubin has a significant positive correlation with 
FK506 plasma level (A), and negative correlation with FK506 dose (B). 
as well as a weaker correlation (r = 0.154) between the FK506 
plasma levels and FK506 doses, with P = 0.001 (data not shown 
graphically) . 
The foregoing correlations in the pooled class I-IV patients 
were even more significant when the patients of class I and IV 
were considered alone (Fig. 10, A and B). 
DISCUSSION 
The pharmacokinetics of FK506 already are reasonably well 
understood in large animals and humans (9, 10). Following an 
intravenous dose in normal subjects, the terminal half-life after 
a redistribution phase is about 9 hours (9). FK506 is metabo-
lized mainly by the liver. However, its clearance is high and 
actually exceeds total hepatic blood flow, implying significant 
extrahepatic clearance. In contrast, cyclosporine is a low-clear-
ance drug (11). With oral dosing, the nature of FK506 absorp-
tion and timing of peak blood (or plasma) levels also appear to 
differ from cyclosporine. In contrast to cyclosporine, bile is not 
needed for FK506 absorption (10).6 Because FK506 may be 
6 Imventarza 0, Furukawa H, Venkataramanan R, et al. The effect 
of bile duct ligation and bile diversion on FK506 pharmacokinetics in 
dogs. (Submitted for publication.) 
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FIGURE 10. The same correlations as in Figure 9, but only in the 
class I and class IV patients. The correlation coefficients were even 
more significant than in Figure 9 when comparisons were between 
optimally functioning (class I) and seriously dysfunctional grafts (class 
IV). 
absorbed over many hours with peak plasma levels that are 
blunted in comparison with cyclosporine (J 1), its oral formu-
lation may have "slow release" qualities with fewer fluctuations 
in plasma concentrations. As far as is known, FK506 has no 
hepatotoxicity (2, 12) or cardiac toxicity (13). 
Most of the foregoing information was used in planning the 
schedules for FK506 dosing and monitoring, which have been 
highly successful in our clinical trials (1-5). However, the 
extent to which graft dysfunction should be taken into consid-
eration for management decisions has not been examined pre-
viously. This factor was predicted to be particularly important 
if the organ grafted was the liver. 
The present study has confirmed this expectation. The func· 
tional state of the liver graft dominated all postoperative phar-
macokinetic variables. If the hepatic graft functioned relatively 
normally from the outset (class I) or even if it was damaged 
significantly but recovered quickly (class II), the same starting 
intravenous and oral doses as those used for kidney, heart, and 
lung transplantation were well tolerated. Plasma FK506 trough 
levels rose during the period of intravenous drug administra-
tion, but the levels promptly receded in the average patient as 
the liver recovered and if oral dosing could be started. Because 
FK506 augments liver regeneration (14) and has other hepa-
totrophic qualities (12), its presence may have facilitated he-
patic recovery from perioperative liver damage. 
In contrast, when perioperative hepatic graft dysfunction did 
not resolve promptly as in class III and IV liver recipients, and 
particularly if FK506 was continued intravenously, the plasma 
levels rose astronomically and often stayed high for days or 
weeks in spite of FK506 dose reductions or discontinuance. 
These patients had a high rate of renal failure, often leading to 
dialysis, which seemed associated with the high plasma levels 
of FK506. Incongruously, this association was not statistically 
significant at any time point, a failure that may reflect the 
heterogeneity of the cases and sample sizes. Most of these 
patients had variable degrees of multiple organ failure in a 
complex setting in which the hepatorenal syndrome, hyperten-
sion, multiple blood transfusions, sepsis, endotoxemia, and the 
need for nephrotoxic antibiotics could have been independent 
or collaborating factors with elevated FK506 blood levels, in 
the genesis of renal failure (15, 16). Recovery from this syn-
drome has not been possible very often in the past without 
resorting to hepatic retransplantation (17). 
FK506 nephrotoxicity could be studied with discrimination 
only in the thoracic organ recipients who did not have preex-
isting kidney or liver disease. The transient rises in plasma 
FK506 levels during intravenous treatment and associated rises 
in BUN or creatinine were reversed partly when the FK506 
doses were reduced or changed to the oral route. In the lung or 
heart-lung recipients, in whom the sole immunosuppression 
was with FK506, an FK506 dose ceiling dictated by nephrotox-
icity was sought. It was not hard to give enough oral drug to 
reach this level. The consequent slow rises in creatinine and 
BUN were quickly responsive to dose reduction. 
Finally, it was important to note that renal failure itself did 
not alter either the daily FK506 doses or the plasma levels. The 
purest information came from the kidney recipients with and 
without postoperative ATN. Not only was the basic FK506 
management the same, but at the end of 60 days, the kidney 
function was identical in patients with immediate versus de-
layed graft function. The observations were consonant with 
information from other sources that essentially no FK506 is 
eliminated by the kidney (9). 
Taken together, the observations from the different kinds of 
organ transplants permit reasonably clear conclusions and rec-
ommendations about management. First, the greatest risk of 
either acute or prolonged over-dosage, as judged by renal dys-
function and by excessive plasma FK506 levels, has been in 
patients with defective drug metabolism caused by hepatic 
dysfunction. The need is clear to consider early dose reductions 
under such circumstances along with frequent monitoring of 
plasma FK506 levels. Second, over-dosing, as defined by high 
FK506 plasma levels, is possible even with normal liver func-
tion, and was associated strongly with perioperative intrave-
nous administration. This became a serious problem only when 
conversion to the oral route could not be done promptly. With 
this conversion, the daily doses of 0.15 mg/kg intravenously 
were increased to 0.3 mg/kg orally. In terms of FK506 availa-
bility, this change was considered to be an absolute dose reduc-
tion since only about 20-30% of FK506 is absorbed from the 
intestine (9). In future cases, smaller doses of FK506 for the 
intravenous induction are advisable-at least in selected cases 
but probably in all. In addition, we are evaluating continuous 
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intravenous infusion instead of a 4-hr infusion twice a day, as 
was our practice during this study. Such an approach has been 
previously recommended for cyclosporine (18). 
The demonstration that FK506 kinetics is drastically altered 
by hepatic dysfunction is a clear warning against over-dosage 
in patients with failing liver grafts under conventional immu-
nosuppression who are switched to FK506 under so-called 
"rescue" circumstances (19). Failure to accurately monitor 
plasma FK506 levels in these patients and to make appropriate 
dose adjustments accordingly could lead systematically to tox-
icity. We have considered nephrotoxicity in this study, but 
serious neurotoxicity was also observed in one of our cardiac 
patients and has been reported in liver recipients (20). The 
extent of drug-related neuropsychiatric problems may be im-
possible to identify in patients dying of liver failure since they 
are prone to such complications in any event (20, 21). 
REFERENCES 
1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain 
A. FK 506 for human liver, kidney, and pancreas transplantation. 
Lancet 1989; 2: 1000. 
2. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under 
FK 506. JAMA 1990; 264: 63. 
3. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ 
transplantation under FK 506. Ann Surg 1990; 212: 295. 
4. Fung JJ, Todo S, Jain A, et al. Conversion of liver allograft 
recipients with cyclosporine related complications from cyclo-
sporine to FK 506. Transplant Proc 1990; 22: 6. 
5. Armitage JM, Kormos RL, Fung J, et al. Preliminary experience 
with FK506 in thoracic transplantation. Transplantation (in 
press). 
6. Jain AB, Fung JJ, Todo S, et a1. Incidence of treatment of rejection 
episodes in primary orthotopic liver transplantation under FK 
506. Transplant Proc 1991; 23: 928. 
7. Shapiro R, Jordan M, Fung J, et al. Kidney transplantation under 
FK 506 immunosuppression. Transplant Proc 1991; 23: 920. 
8. Tamura K, Kobayashi M, Hashimoto K, et al. A highly sensitive 
method to assay FK-506 levels in plasma. Transplant Proc 1987; 
19 (suppl 6): 23. 
9. Venkataramanan R, Jain A, Cadoff E, et al. Pharmacokinetics of 
FK 506: preclinical and clinical studies. Transplant Proc 1990; 
22: 52. 
10. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic 
dysfunction and T tube clamping on FK 506 pharmacokinetics 
and trough concentrations. Transplant Proc 1990; 22: 57. 
11. Ptachcinski RJ, Venkataramanan R, Burckard GJ. Clinical phar-
macokinetics of cyc1osporine. Clin Pharmacokinet 1986; 11: 107. 
12. Starzl TE, Porter KA, Mazzaferro V, Todo S, Fung J, Francavilla 
A. Hepatotrophic effects ofFK506 in dogs. Transplantation 1991; 
51: 67. 
13. Kang Y, Mazer MA, De Wolf AM, et al. Acute hemodynamic effects 
of FK 506 during and after orthotopic liver transplantation. 
Transplant Proc 1990; 22: 21. 
14. Francavilla A, Barone M, Todo S, Zeng Q, Porter KA, Starzl TE. 
Augmentation ofrat liver regeneration by FK 506 compared with 
cyc1osporine. Lancet 1989; 1: 1248. 
15. McCauley J, Van Thiel D, Starzl TE, Puschett JB. Acute and 
chronic renal failure after liver transplantation. Nephron 1990; 
55: 121. 
16. McCauley J, Fung JJ, Jain A, Todo S, Starz! TE. The effects of 
FK 506 upon renal function after liver transplantation. Trans-
plant Proc 1990; 22: 17. 
17. Starzl TE, Demetris AJ. Liver transplantation. Chicago, IL: Year 
Book, 1990:43-56,57-70,85. 
18. Kahan BD, Givelel J. Optimization of cyclosporine therapy in renal 
transplantation by a pharmacokinetic strategy. Transplantation 
1988; 46: 631. 
19. Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft 
recipients from cyclosporine to FK 506 based immunosuppres-
sion: benefits and pitfalls. Transplant Proc 1991; 23: 14. 
20. Reyes J, Gayowski T, Fung J, Todo S, Alessiani M, Starzl TE. 
Expressive dysplasia possibly related to FK506 in 2 liver trans-
plantation recipients. Transplantation 1990; 50: 1043. 
21. Starzl TE, Schneck SA, Mazzoni G, et al. Acute neurological 
complications after liver transplantation with particular refer-
ence to intraoperative cerebral air embolus. Ann Surg 1978; 187: 
236. 
Received 14 August 1990. 
Accepted 3 December 1990. 
